Pamela R Kearns

UNVERIFIED PROFILE

Are you Pamela R Kearns?   Register this Author

Register author

Pamela R Kearns

Publications by authors named "Pamela R Kearns"

Are you Pamela R Kearns?   Register this Author

17Publications

-Reads

Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.

J Clin Oncol 2018 May 2;36(13):1330-1338. Epub 2018 Mar 2.

Lia Gore, University of Colorado School of Medicine/Children's Hospital Colorado, Aurora, CO; Pamela R. Kearns, University of Birmingham, Birmingham, West Midlands; Donna Lancaster, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Maria Lucia de Martino Lee, Support Group for Children and Adolescents with Cancer; Carmino Antonio De Souza, University of Campinas, São Paulo, Brazil; Yves Bertrand, L'Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France; Nobuko Hijiya, Ann and Robert H. Lurie Children's Hospital of Chicago, and Northwestern University Feinberg School of Medicine, Chicago, IL; Linda C. Stork, Oregon Health & Science University, Portland, OR; Nack-Gyun Chung, The Catholic University of Korea, Seoul St. Mary's Hospital; Jong Jin Seo, University of Ulsan College of Medicine, and Asan Medical Center, Seoul, Republic of Korea; Rocio Cardenas Cardos, Instituto Nacional De Pediatria, Mexico City, Mexico; Tapan Saikia, Prince Aly Khan Hospital, Mumbai, India; Franca Fagioli, Regina Margherita Hospital, Turin, Italy; Judith Landman-Parker, Hôpital Enfants Armand-Trousseau, Paris, France; Andrew E. Place, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Karen R. Rabin, Texas Children's Cancer Center, and Baylor College of Medicine, Houston, TX; Mariana Sacchi and Rene Swanink, Bristol-Myers Squibb, Princeton, NJ; C. Michel Zwaan, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands; Pamela R. Kearns and C. Michel Zwaan, Innovative Therapies for Children with Cancer Consortium, European Union.

View Article
May 2018

10-year report on the European Paediatric Regulation and its impact on new drugs for children's cancers.

Lancet Oncol 2018 Mar;19(3):285-287

Innovative Therapy for Children with Cancer, Europe; SIOPE Brussels, Belgium; Department of Clinical Research, Gustave Roussy, Paris-Saclay University, Villejuif, France.

View Article
March 2018

The development of targeted new agents to improve the outcome for children with leukemia.

Expert Opin Drug Discov 2016 Nov 27;11(11):1111-1122. Epub 2016 Sep 27.

a Department of Pediatric Oncology, Hematology and Stem Cell Transplantation , Hospital Niño Jesús , Madrid , Spain.

View Article
November 2016

PEPtalk: postexposure prophylaxis against varicella in children with cancer.

Arch Dis Child 2011 Sep 28;96(9):841-5. Epub 2011 Jun 28.

Division of Clinical Sciences, St George's, University of London, London, UK.

View Article
September 2011

Expression of CD133 on leukemia-initiating cells in childhood ALL.

Blood 2009 Apr 15;113(14):3287-96. Epub 2009 Jan 15.

Bristol Institute for Transfusion Sciences, Bristol, United Kingdom.

View Article
April 2009

Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia.

Blood 2007 Jan 26;109(2):674-82. Epub 2006 Sep 26.

Bristol Institute for Transfusion Sciences, University of Bristol, BS10 5ND, United Kingdom.

View Article
January 2007